New insider activity at Lemaitre Vascular ( (LMAT) ) has taken place on August 14, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Lawrence Jasinski recently sold 976 shares of Lemaitre Vascular stock, amounting to a total transaction value of $90,553.
Recent Updates on LMAT stock
In the past 24 hours, LeMaitre Vascular reported strong Q2 2025 financial results, showcasing a 15% increase in sales and a 16% rise in earnings per share. The company highlighted successful product launches, particularly the Artegraft, which contributed significantly to sales growth. Despite a catheter recall and increased operating expenses, the company’s financial health remains robust, supported by a strong cash flow and increased revenue guidance. Analyst Michael Petusky upgraded LeMaitre to Outperform, citing the company’s 15% organic growth and 25% operating margins as indicators of a promising second half of 2025 and an even better 2026. The company’s strategic initiatives, including expansion of its sales force and tariff-driven price adjustments in China, are expected to sustain its upward trajectory.
Spark’s Take on LMAT Stock
According to Spark, TipRanks’ AI Analyst, LMAT is a Outperform.
Lemaitre Vascular’s strong financial performance and positive earnings call are the most significant factors driving the stock’s score. The company’s robust growth and profitability metrics, along with a positive outlook, are key strengths. However, the high valuation and overbought technical indicators present potential risks.
To see Spark’s full report on LMAT stock, click here.
More about Lemaitre Vascular
YTD Price Performance: 3.77%
Average Trading Volume: 156,322
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.14B